On March 10th, Xi'an International Medical Center Hospital held the completion ceremony and academic exchange activity of the Yttrium-90 treatment of liver tumors project. The completion of this project marks a new level of comprehensive diagnosis and treatment for liver malignant tumors in the hospital, bringing new hope to more advanced liver cancer patients.

Experts related to ecological environment, Chairman Shi Jin of International Medicine, President Liu Ruixuan, Vice President Sun Wenguo, President Yin Qiang of Xi'an International Medical Center Hospital, General Manager Wang Zhifeng, and nearly 200 people from various specialized hospitals and departments participated. Han Guohong, Executive Director of the Digestive Disease Hospital, presided over the ceremony.

At the completion ceremony, Dean Yin Qiang delivered a speech and warmly welcomed the leaders and guests who attended the ceremony! He stated that after the project is implemented, the hospital will rely on a strong team of expert talents and gather internationally advanced diagnosis and treatment technologies to quickly drive and improve the level of liver cancer diagnosis and treatment in Shaanxi Province and even the northwest region, filling the gap in the "yttrium 90 microsphere selective internal radiation therapy" in the region, and bringing hope for more liver cancer patients to achieve clinical cure and return to normal life.

Liver malignant tumors are one of the most common causes of cancer death in China, known as the "king of cancer". Every year, China adds 460000 new patients with primary liver cancer and over 200000 patients with liver metastases. Most liver cancer patients are already in the middle and late stages when they are discovered.

Yttrium-90 microsphere selective internal radiation therapy is the use of microcatheters to inject microspheres containing radioactive substance Yttrium-90 into the hepatic artery. The microspheres follow the blood flow to the liver tumor site and release β X-rays efficiently kill tumors. Due to its high energy, small radiation range, short half-life, precise radiation, and no damage to surrounding normal liver tissue, it provides precise strikes against tumors from the inside out, earning the industry a reputation as a precision guided "nuclear weapon" for liver cancer treatment.

On February 28, 2023, our hospital successfully obtained the radiation safety license and radiation diagnosis and treatment license for yttrium-90 microsphere therapy, becoming a domestic hospital specializing in the construction of DSA yttrium-90 interventional therapy center in nuclear medicine and obtaining the license access specification qualification.

Han Guohong, Executive Director of Digestive Disease Hospital, introduced that compared with other traditional treatment methods, yttrium-90 microsphere selective internal radiation therapy has a dual therapeutic effect of strong tumor reduction and increased residual liver volume, which can accurately target and kill cancer tissue while almost not damaging normal liver tissue; The complete elimination rate of lesions is high, while reducing microvascular invasion and reducing the recurrence rate after transplantation; In addition, the treatment cycle is short, there are few adverse reactions, and the impact on the patient's physical condition is small, which can significantly improve the quality of life of patients with advanced liver cancer. At present, the digestive hospital has prepared for comprehensive reception, evaluation, and implementation of Yttrium-90 microsphere surgery.

Amidst enthusiastic applause, group leaders and hospital leaders jointly cut the ribbon for the completion of the Yttrium 90 treatment of liver tumors project.

After the completion ceremony, the hospital held an "online offline" academic exchange activity. Many experts in the field of liver diseases at home and abroad discussed the domestic and foreign cases of yttrium-90 in the treatment of liver tumors. Professor Yang Aimin, First Affiliated Hospital of Xi'an Jiaotong University, gave a lecture on "nuclear medicine Experience in T 90Y-SIRT Accurate Radiation Dose Estimation"; Professor Zhang Lin from Tsinghua Changgeng Hospital explained the current status and exploration of yttrium 90 treatment for liver malignant tumors through illustrated and textual methods. Experts bring the latest theory and advanced experience of yttrium 90 treatment technology to discuss the "yttrium era" of liver tumor treatment.

The Yttrium-90 treatment of liver tumors project has officially launched, marking a milestone in the precise treatment system for liver malignancies at Xi'an International Medical Center Hospital. It plays an important demonstration role in the comprehensive cancer prevention and treatment plan of the "Healthy China" initiative. Xi'an International Medical Center Hospital will establish an advanced management team with advanced concepts, establish an efficient and mature operating mechanism, and build a high-quality and efficient service system, so that the general public can access higher quality medical and health services at their doorstep.